To improve therapeutic strategies, we propose to dissect primary (intrinsic) resistance of a given melanoma to a panel of inhibitors with distinct modes of action. Our preliminary studies demonstrate that following a given drug treatment, melanoma cells not only enter apoptosis and necrosis, but they can also respond via one of two senescent phenotypes. These include either a """"""""natural"""""""" irreversible (terminal) senescence, or a second type of senescence that we have recently observed, which, while bearing the hallmarks of classical senescence, is reversible. Due to the fact that this reversible senescence can have tumor-protective properties and give rise to a proliferative population, we term it """"""""pseudo"""""""" senescence. This proposal is designed to define the role of therapy-induced senescence in melanoma and to develop novel therapeutic strategies that promote irreversible senescence and sensitize cells to therapy-induced apoptosis. In the first aim we will define therapy-induced senescence and will determine the molecular mechanisms underlying the heterogeneous responses to signaling modulators/inhibitors, including novel BRAF dimer inhibitors. It is likely that each type of senescence will have different outcomes, ranging from eventual cell death to the increase of invasion followed by re-growth. Our studies will assess the different cell fates to best define the mechanisms leading to the terminal senescence, and ultimately, cell death in combination with other reagents. In the second aim, we will develop therapeutic strategies for maximizing the induction of senescence/cell death in melanomas. We will test the hypothesis that pro-survival autophagy modulates the long-term responses to senescence induction and will develop combination therapies to induce irreversible senescence.
This proposal addresses the question why not all cancer cells within a tumor that are positive for the BRAF mutation are being killed. Besides dying when exposed to BRAF inhibitors, we have defined a senescence state, pseudo-senescence, where cells are just dormant and can recover to then grow again. We intend to molecularly dissect the two different senescence states and develop combination therapies that drive cells into irreversible senescence while disallowing cells to enter the pseudo-senescence state.
| Noguera-Ortega, Estela; Amaravadi, Ravi K (2018) Autophagy in the Tumor or in the Host: Which Plays a Greater Supportive Role? Cancer Discov 8:266-268 |
| Jenkins, Russell W; Aref, Amir R; Lizotte, Patrick H et al. (2018) Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov 8:196-215 |
| Emptage, Ryan P; Lemmon, Mark A; Ferguson, Kathryn M et al. (2018) Structural Basis for MARK1 Kinase Autoinhibition by Its KA1 Domain. Structure 26:1137-1143.e3 |
| Barnoud, Thibaut; Budina-Kolomets, Anna; Basu, Subhasree et al. (2018) Tailoring Chemotherapy for the African-Centric S47 Variant of TP53. Cancer Res 78:5694-5705 |
| Liu, Shujing; Zhang, Gao; Guo, Jianping et al. (2018) Loss of Phd2 cooperates with BRAFV600E to drive melanomagenesis. Nat Commun 9:5426 |
| Pathria, Gaurav; Scott, David A; Feng, Yongmei et al. (2018) Targeting the Warburg effect via LDHA inhibition engages ATF4 signaling for cancer cell survival. EMBO J 37: |
| Reyes-Uribe, Patricia; Adrianzen-Ruesta, Maria Paz; Deng, Zhong et al. (2018) Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma. Oncogene 37:4058-4072 |
| Rebecca, Vito W; Nicastri, Michael C; Fennelly, Colin et al. (2018) PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer. Cancer Discov : |
| Kaur, Amanpreet; Ecker, Brett L; Douglass, Stephen M et al. (2018) Remodeling of the Collagen Matrix in Aging Skin Promotes Melanoma Metastasis and Affects Immune Cell Motility. Cancer Discov : |
| Chen, Gang; Huang, Alexander C; Zhang, Wei et al. (2018) Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 560:382-386 |
Showing the most recent 10 out of 144 publications
